BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NeurogesX, Inc. Prices Initial Public Offering


5/2/2007 11:23:50 AM

SAN CARLOS, Calif., May 2 /PRNewswire-FirstCall/ -- NeurogesX, Inc. announced today the initial public offering of 4,000,000 shares of common stock at a price to the public of $11.00 per share. The Company has granted an option to the underwriters to purchase up to an additional 600,000 shares to cover over-allotments, if any.

NeurogesX's common stock will trade on the NASDAQ Global Market under the symbol "NGSX." The offering is expected to close on May 7, 2007, subject to customary closing conditions.

Morgan Stanley & Co. Incorporated acted as the sole book running and lead manager for the offering. Pacific Growth Equities, LLC, Lazard Capital Markets LLC and Susquehanna Financial Group, LLLP acted as co-managers for the offering.

The offering is made only by means of a prospectus, copies of which may be obtained from the Morgan Stanley & Co. Incorporated prospectus department, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at (212) 761-6775 or by emailing prospectus@morganstanley.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About NeurogesX, Inc.

NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies for neuropathic pain.

NeurogesX Stephen Ghiglieri (650) 508-2116 The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 scarrington@theruthgroup.comjrando@theruthgroup.com

NeurogesX, Inc.

CONTACT: Stephen Ghiglieri of NeurogesX, Inc., +1-650-508-2116; orInvestors - Media, Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES